Early ReportAssociation between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
Introduction
Clostridium difficile antibiotic-associated diarrhoea is a common, iatrogenic, nosocomial disease associated with substantial morbidity and mortality.1 Pathogenic strains of C difficile produce the protein exotoxins toxin A and toxin B. These cytotoxic, enterotoxic, and proinflammatory toxins induce colonic mucosal injury, diarrhoea, and in severe cases, pseudomembranous colitis.1, 2C difficile is endemic in hospitals and long-term care facilities throughout the world.3, 4, 5, 6, 7 In a previous study, we noted that 31% of patients who received antibiotics in acute-care medical wards were colonised by C difficile while in hospital. 56% of these developed C difficile diarrhoea; the remainder were symptomless carriers.3
Most patients with C difficile diarrhoea respond well to medical therapy that includes discontinuation of the inciting antibiotic and treatment with metronidazole or vancomycin.1, 8, 9 However, despite successful treatment of initial episodes, recurrence of diarrhoea after withdrawal of specific antibiotic therapy is a substantial clinical difficulty. Recurrence rates of 5-65% have been reported, dependent on definition of recurrence and population studied.10, 11, 12, 13, 14
We reported high concentrations of serum IgG against toxin A in symptomless carriers of C difficile.3 On the basis of this finding, and on results of our previous studies, we postulated that host immune response to toxin A during an episode of C difficile diarrhoea could affect risk of recurrence.15, 16
Section snippets
Patients
All patients with C difficile diarrhoea at Beth Israel Deaconess Medical Center, Boston, USA, between Jan 5, and May 22, 1998, were eligible for study enrolment. Diarrhoea was defined as a change in bowel habit with three or more unformed bowel movements per day for at least 2 days. C difficile diarrhoea was defined as diarrhoea not attributed to any other cause, that arose during or within 30 days of antibiotic therapy, and that was associated with a positive stool toxin for C difficile
Results
We prospectively identified 63 cases of C difficile diarrhoea during the 5-month study period. The study population was made up predominantly of elderly white patients, most had clinically significant comorbid disease, and almost two thirds (39, 62%) had severe or extremely severe underlying disease at hospital admission.
The presence or absence of recurrent diarrhoea could not be determined in 19 (30%) patients with C difficile diarrhoea because they died before the end of the 60-day follow-up
Discussion
In our prospective cohort study of 63 patients, we found that an acquired immune response to C difficile toxin A during an initial episode of C difficile diarrhoea is associated with a substantially reduced risk of recurrent diarrhoea. Patients with a single episode of C difficile diarrhoea have significantly higher concentrations of serum IgM against toxin A by day 3 of their illness and significantly higher serum concentrations of IgG against toxin A on day 12, than patients who later had
References (28)
- et al.
Incidence and impact of Clostridium difficile infection in the UK, 1993–1996
J Hosp Infect
(1998) - et al.
Clostridium difficile colitis: factors influencing treatment failure and relapse–a prospective evaluation
Am J Gastroenterol
(1998) - et al.
Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
J Pediatr
(1991) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Assessing illness severity: does clinical judgment work?
J Chronic Dis
(1986) - et al.
Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding
Gastroenterology
(1992) - et al.
Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea
Diagn Microbiol Infect Dis
(1994) - et al.
Clostridium difficile colitis
N Engl J Med
(1994) Pathogenesis of Clostridium difficile -associated diarrhoea
Eur J Gastroenterol Hepatol
(1996)- et al.
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A
N Engl J Med
(2000)